Pyrimidine modifications therapeutics

Examples of this type of structural modification were described in 1985 by Taylor et al. [152,153]. The rationale for the preparation of these compounds was that metabolic oxidation at position 7 of the pyrido[3,4-g]pyrimidine ring system would be blocked and that the extra CH2 groups in the 7,10-bridge would enhance lipophilicity. It was hoped that these tied back analogues might show improved enzyme binding properties and increased therapeutic potency. 

Nucleobase Modifications In the search for new therapeutic derivatives, substituted triazole rings have been introduced on both pyrimidines [2] and purine nucleosides [3-5] (Figure 10.1). Among all the synthesized compounds, some... 

---